Mobile

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metfo...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004032-48

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin Treatment twice daily in Patients with Type 2 Diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the effect of 1 mg tesaglitazar once daily versus placebo once daily given as add?on therapy to metformin on the steady state exposure (AUCss) of metformin in patients with type 2 diabetes with a serum creatinine within normal range and having CrCL>70 mL/min or CrCL≤70 to ≥50mL/min, by assessment after a 12-week randomized treatment period.

Critère d'inclusion

  • type II diabetes mellitus

Liens